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Abstract
Incorporating proteins with nanomaterials is an effective way to enhance the stability and
function of proteins. The protein-nanomaterials hybrid systems have been extensively
applied in drug delivery and biocatalysis. This thesis focuses on the different interactions
between proteins and nanomaterials. Three sub-projects have been studied as follows;
1) Chemical interaction: Gold nanoparticles with a particle size of 15nm were applied to
label bovine serum albumin (BSA), a globular protein, for realizing a colorimetric protein
assay. The results of FTIR and Raman spectra indicate that gold nanoparticles bond to BSA
via the amine bonds. The surface plasma resonance (SPR) of gold nanoparticle labelled BSA
shows a linear relationship with the concentration of BSA.
2) Electrostatic interaction: To make enzyme stable and recyclable in biocatalysis, the
enzyme, carbonic anhydrase (CA), was immobilized on zinc oxide (ZnO) nanorods via
electrostatic interaction. The highest immobilization ratio (60%) is achieved at pH 8.0. The
CO2 capturing by the immobilized CA has been investigated. It is found that a 2.2×2.2cm
ZnO nanorod chip with 0.75mg immobilized CA could capture up to 6mmol CO2 in 100mL
water.
3) Multiple interactions: Via hydrogen bond and electrostatic interaction, basic fibroblast
growth factor (bFGF) was incorporated within chitosan and silica nanoparticles, respectively.
In vitro release tests indicate that chitosan and silica nanoparticles could achieve a sustained
bFGF release up to 230 and 180 hours, respectively. The bFGF-loaded nanoparticles were
afterwards immobilized within HEMA hydrogel. The nanoparticle-HEMA nanocomposites
can provide a localized sustained protein release without systematic absorption.
The incorporation of proteins with nanomaterials can enhance the stability and activity of
proteins which are otherwise prone to denaturation.

Keywords
Nanoparticle, Gold, Protein Assay, Zinc Oxide, Carbonic Anhydrase, Hydrogel, Chitosan,
Silica
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Chapter 1
Introduction, Motivation and Objective
1.1 Introduction
The improvement of modern biotechnologies leads to a significant increase in the
application of proteins in bio-medicine and in bio-catalysis. For example, the genetic
recombination technology has brought a remarkable expansion in the application of
proteins in the treatment of a myriad of disease
evolution

[2]

and high-throughput screening

[1]

. In addition, the progress in directed

[3]

techniques has enabled the broad

application of enzyme catalysts in the chemical industry to manufacture products ranging
from simple commodity chemicals to pricy drug substances

[4]

. It is noted that protein

activities are highly dependent on its flexible and sensitive conformational structures.
External factors such as pH, temperature, surface interaction, as well as contaminants,
may compromise the conformational and even the chemical structure of proteins [5].
The flexible and instable structure of proteins usually hinders their applications: 1)
Industrial applications of enzymes for bio-catalysis are usually at high temperature, high
salt concentrations, as well as in the presence of surfactants

[6]

. Only few enzyme

catalysts are able to withstand such extreme conditions. 2) In many instances, the high
solubility of some protein enzymes in reaction media may prevent them from being
recycled and reused with current standard reactors in an economically feasible way. 3)
Human body fluids contain a myriad of enzymes, hormones, cells and metabolites.
Protein may be absorbed to or be cleft by those components and lose activities rapidly
after being administered [7].
Incorporating protein within nanomaterials provides a promising solution to overcome
those barriers met by bio-medical and bio-catalytic application of proteins. Nanomaterials
are materials with at least one of their dimention in the range of 1-100 nm. The large
surface area-to-volume ratios of nanomaterials, such as nanoparticles and nanorods, make
them potentially highly efficient protein carriers [8,9].
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Among nanomaterials, nanoparticles are usually used as drug delivery systems and
enzyme immobilization supporters. These nanoparticle-based systems are stable, nontoxic, non-immunogenic, and biocompatible
nanoparticles can improve their stability
them to certain organs and tissues

[10, 11]

[12, 13]

[14]

. Incorporating proteins into those

, retend their release rate

[13]

and direct

. Nanorods are often utilized as enzyme

immobilization supporters for bio-catalysis. Attachment of soluble enzyme to insoluble
nanorods substrate improves enzyme stability and activity [15, 16], and makes the efficient
enzyme reuse economically feasible. The immobilized enzymes are usually used as
biosensor for the detection of various small molecules such as glucose [17] and phenol [18].
Proteins are incorporated to nanomaterials in three different ways: being attached to
surface, embedded into the porous scaffold, or encapsulated inside the materials. Various
protein-nanomaterials interations participate in the incorporation process. The most
common ones are chemical interaction, hydrogen bond and electrostatic interaction [19].
Many ligands in proteins molecules, such as thiols, disulfides, phosphines, amines, and
carboxylates, are able to interact with gold nanoparticles and form chemical bonds with
similar strength to covalent bonds

[20]

. Additionally, the surface plasmon resonance

indigenous to gold nanoparticles makes them show a strong and stable red color after
protein binding [21]. This easily detectable color and tight protein binding allow gold
nanoparticles to be a potential protein label for quantitative protein assay.
Electrostatic interaction is the most common protein-nanoparticle interaction

[19]

. Some

proteins are amphiprotic molecules, while the surfaces of nanoparticles can be modified
with positively or negatively charged function groups. By adjusting the environmental pH
value, proteins and nanomaterials could be oppositely charged. The resultant static
electriciry force makes proteins tightly bind to nanomaterials.
Hydrogen bonding is the electromagnetic attractive interaction of a hydrogen atom and an
electronegative atom, such as nitrogen or oxygen that comes from another chemical
group. Hydrogen bonds provide most of the directional interactions that underpin protein
folding, protein structure and molecular recognition [22]. In contacting with nanomaterials
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rich in functional groups, proteins could easily be incorporated into the nanomaterials via
hydrogen bond.

1.2 Motivation
1.2.1 Protein-nanoparticle binding via chemical interaction
The nature of the chemical interaction between proteins and gold nanoparticles makes
incorporated proteins unlikely to be detached from their carriers. Other than the more
popular application as a protein delivery system, the gold nanoparticle could be utilized
as a protein label for colorimetric protein assay.
The accuracy of current standard colorimetric protein assay methods is usually interfered
by factors such as protein structre, purity and the existence of other molecular

[23]

.

Because of their strong surface plasma resonance, gold nanoparticles are readily
detectable by spectrometers. The multiple high-strength bonds of protein to gold
nanoparticles may make the resultant protein-gold nanoparticle complex independent of
the interferencing factors that compromise the accuracy of other standard colorimetric
protein assay methods.
The concentration of gold nanoparticles could be easily quantified by measuring the
intensity of their surface plasma resonances. By fixing the ratio of protein to gold
nanopartilcles, the concentration of loaded protein could be easily calculated by
multiplying the protein to gold nanopartilcle ratio with gold nanopartilcle concentration

1.2.2 Protein-nanomaterial binding through electrostatic interaction
The electrostatic interaction between oppositly charged protein and nanomaterial is
usually strong and stable. Such tight and stable protein-nanomaterial binding could be
applied to get an enzyme-nanomaterial complex that is resistant to the environmental
turbulence present in reactors.
The biosafety and biocompatibility of zinc oxide (ZnO) make ZnO nanorod a superb
material for enzyme immobilization [24]. The isoelectric points (pI) of the model enzyme,
carbonic anhydrase (CA), and ZnO are 6.7-7.9 [25] and 9.5, respectively. Incubating CA in
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the presence of ZnO nanorods in a medium which could make them oppositely charged
could incorporate CA onto ZnO nanorods via electrostatic interaction. Such immobilized
enzymes are more stable and easier to be reused than free enzymes.

1.2.3 Protein-nanomaterial binding via multiple interactions
Due to their complex nature, proteins are usually incorporated with nanomaterials
through multiple interactions, especially electrostatic forces and hydrogen binding.
Chitosan is a polymer with both positively charged side chains and rich amino and
hydroxyl groups. Protein could be incorporated into chitosan nanoparticles via
electrostatic forces and hydrogen bonding [26, 27]. Silica nanoparticles are characterized by
their honeycomb-like porous structure with hundreds of empty channels. It is reported
that proteins are absorbed onto silica through multiple binding: 1) Protein’s carbonyl
groups interact with silica’s vicinal hydroxyl groups via electrostatic interaction. 2) Imido
groups in proteins form hydrogen bonds with individual hydroxyl groups on silica surface
[28]

. The obtained protein-nanomaterial complexs are usually used as protein delivery

systems.

1.3 Objectives
The objective of this research is aimed at investigating the protein-nanomaterial
interactions via protein-nanomaterial complexes. Based on specific protein-nanomaterial
interations, corresponding protein carriers are developed and their characteristics,
activities and possible applications are investigated.

It can be divided into three

individual parts:
1) To investigate the interaction between protein and gold nanoparticles. To utilize gold
nanoparticle as a protein label to develop a cholorometric protein assay method.
2) To find the proper condition to immobilize protein onto nanorods through electrostatic
interaction. To utilize the immobilized protein for CO2 capture.
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3) To load protein into chitosan and silica nanoparticle via multiple protein-nanoparticle
interaction. Additionally, apply the protein-loaded nanoparticles to achieve a sustained
topical protein release.

1.4 Outline of thesis
Chapter 1: This chapter introduces the problems to be addressed and the techniques that
would be used in the thesis, the motivation behind the selection of the techniques and the
research objectives.
Chapter 2: The literature review summarizes current application of nanoparticles as a
protein carrier and the utilization of nanoparticles and nanorods as substrates for enzyme
immobilization.
Chapter 3: This chapter introduces the experimental materials and methods.
Chapter 4: In this chapter, the interaction of gold nanoparticles with protein is
investigated and the gold nanoparticle is exploited as a protein label. Bovine serum
albumin is used as model protein. Release pattern of gold nanoparticle labeled BSA from
gelatin microspheres is studied.
Chapter 5: This chapter looks into the protein immobilization onto ZnO nanorods.
Electrostatic force is utilized to immobilize carnonic anhydrase, the model protein onto
ZnO nanorods. CO2 capturing ability of the obtained system is studied.
Chapter 6: In this chapter, model protein bFGF is incorporated into chitosan and silica
nanoparticles via multiple protein-nanomaterial interaction. The bFGF loaded
nanoparticles are applied in combination of hydrogel to achieve a sustained topical bFGF
delivery.
Chapter 7: This chapter summarizes the research and puts forward the future work.
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Chapter 2
Literature Reviews
Nanomaterials are materials with at least one of their dimention in the range of 1-100 nm
[1]

. Being complex mixtures, they may absorb light like a dye and appear to dissolve like

any other small molecules. Their actual behaviours are often different and are usually the
result of the different components of the material [2]. Nanomaterials have an exceptionally
high surface area to volume ratio; this is one of the reasons for some of their unusual
properties

[3]

. In many cases the exact composition of the surface of the nanomaterials

dictates their final applications [4,5]. For example, a nanoparticle designed to interact with
biological systems will have suitable functional groups attached to its surface [6].
Nanomaterials are used for various fields such as fiber and textiles
energy

[11,12]

, and biomedical sciences

[13-15]

[7]

, agriculture

[8-10]

,

. In biomedical applications, nanomaterials

are usually used as protein carriers. Such carriers are superior to other more traditional
ones in many aspects: They can insulate proteins from interaction with the environment,
protect proteins from premature degradation, enhance proteins’ absorption and
bioavailability, and improve proteins’ intracellular penetration

[16]

. As for the bio-

catalysis, nanomaterials are usually applied to immobilize enzyme catalysts. In this
chapter, we will introduce the application of nanomaterials as protein carriers and
supporters to immobilize enzymes.

2.1 Nanomaterials as protein carriers
Nanoparticles are the most investigated nanomaterial for protein delivery. Biological
agents, such as peptides, enzyme and siRNA, face a major barrier in pharmaceutical
application: being easily degraded, they usually have very short half lives

[17]

.

Nanoparticle protein carriers provide unparallel freedom to modify fundamental
properties of those biological agents such as stability, half-life, release pattern, solubility,
and immunogenicity. The nanoparticle based delivery of biological agents has improved
over the years and many of them, such as liposomal verteporfin developed by Novartis,
have made their ways into the clinic trial and commercialization

[18]

. A myriad of
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materials are exist to be used as nanoparticle matrix, they can be roughly divided into two
categories: biodegradable polymers and inorganic materials. Selection of nanoparticle
matrix depends on the encapsulation efficiency, improvement of bioavailability and
retention time of the final product. The desired materials are generally achieved by hit
and trial method [19].

2.1.1 Biodegradable polymeric nanoparticle
Biodegradable polymeric nanoparticles are the most studied protein nano-carriers and
many of them have been put in clinical trial or commercialized

[18,20]

. Proteins are either

bound to surface or encapsulated inside the nanoparticles. These nano-medicines are
stable in blood, non-toxic, non-immunogenic, non-inflammatory, do not activate
neutrophils, biodegradable, and applicable to various molecules such as small molecules,
proteins/ peptides, and nucleic acids

[21-23]

.

Countless work has been conducted to

develop effective biocompatible and biodegradable polymers for nanoparticles. Despite
of the large amount of developed polymers, only a very small proportion of them have
been approved by FDA for human use. Gelatin and chitosan are two of the FDA
approved, low cost, and safe biodegradable polymers for nanoparticles.

2.1.1.1

Gelatin nanoparticles

Gelatin is a biodegradable, non-toxic polymer with extensive applicationd in food and
medical products

[24]

. It is obtained by controlled hydrolysis of the collagen, a major

component of skin, bones and connective tissue [25]. Both acid and alkali can be used as to
extract gelatin. The acid-extracted gelatin is designated Type A, whereas the product of
the alkaline extraction is referred to as Type B
gelatin are 7-9 and 4-5, respectively

[26]

[24]

. The isoionic point for type A and B

. Type A gelatin has a greater intrinsic viscosity

than that of type B. Three groups of amino acids are predominant in the gelatin molecule.
Glycine and alanine account for about one-third to half of the total amino acid residues in
type B and type A gelatin respectively. Meanwhile, approximately one-fourth of the
amino acid residues in both type of gelatins are proline

[24]

. Such structure offers many

possibilities for chemical modification and covalent drug attachment. Both type of
gelatine can be used as nanoparticle matrix. Gelatin nanoparticles can be prepared by
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various techniques such as coacervation

[27]

, desolvation/ nanoprecipitation

[28, 29]

, and

emulsion [30].
Coacervation is a process during which a homogeneous solution of charged
macromolecules undergoes liquid-liquid phase separation, giving rise to a polymer-rich
dense phase at the bottom and a transparent solution above. Salt or alcohol is normally
added to the solution to promote coacervation and control the degree of crosslinking that
resulted in desired nanoparticles [27].
Briefly, desolvation / nanoprecipitation require two solvents that are miscible. In
desolvation process, the nonsolvent phase is added slowly to the solvent phase that
containing polymer

[28]

. As for the nanoprecipitation process, the solvent phase that

containing polymer is added to the non-solvent phase

[29]

. The interfacial turbulence

generated during solvent displacement is the force to form nanoparticles. Subsequently a
violent spreading is observed because of mutual miscibility between the solvents. The
nano-sized droplets formed in the process are rapidly stabilized by the stabilizing agent,
until diffusion of the solvent is complete and polymer solidification has occurred. For
gelatin, the desolvation process is usually a two steps process, gelatin is first dissolved to
make a homogeneous aquesous solution, desolvation reagent is added to the solution to
get high molecular gelatin. The low molecular gelatin fractions present in the supernatant
were discarded. The high molecular fractions present in the sediment were re-dissolved in
acidic water and then desolvated to form nanoparticles [28]. Crosslinkers are usually added
at the second desolvation step to stabilize the nanoparticles.
Emulsion method is a simple solvent evaporation technique based on a single water-in-oil
emulsion and stabilized by the use of cross-linking agent

[30]

. The encapsulating polymer

is dissolved in a partially water soluble solvent which is saturated with water to ensure
the initial thermodynamic equilibrium of both liquids. Subsequently, the polymer-water
saturated solvent phase is emulsified in an aqueous solution containing stabilizer, leading
to solvent diffusion to the external phase and the formation of nanoparticles. Finally, the
solvent is eliminated by evaporation or filtration, according to its boiling point

[31]

. In

fact, to produce the precipitation of the polymer and the consequent formation of
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nanoparticles, it is necessary to promote the diffusion of the solvent of the dispersed
phase by dilution with an excess of water when the organic solvent is partly miscible with
water or with another organic solvent in the opposite case.

2.1.1.2

Chitosan nanoparticles

Chitosan is a modified natural polymer prepared by the partial deacetylation of
crustacean derived natural biopolymer chitin [32], it is found in a variety of forms differing
in molecular weight and degree of deacetylation. According to Kean’s reviews, no toxic
effect was noted after chitosan is injected, subcutaneous implanted, oral administered and
mucosa applied [33,34]. The rate and extent of chitosan biodegradation in living organisms
are dependent on the degree of deacetylation

[35,36]

. Increasing degree of deacetylation

decreases the decomposition rate. It is likely that, given adequate time and appropriate
conditions, the chitosans would degrade sufficiently for consequent excretion. Given its
superb non-toxicity, biologically compatibility, chitosan is approved for dietary
applications in Japan, Italy and Finland
in wound dressings

[38]

[37]

and it has been approved by the FDA for use

. Chitosan nanoparticles can be prepared by four methods: ionic

gelation, microemulsion, precipitation and reverse micellar method [39].
Ionic gelation is based on electrostatic interaction between amine group of chitosan and
negatively charge groups of polyanion such as tripolyphosphate

[40,41]

. Comparing to

chemical cross-linking, such reversible physical cross-linking avoids the possible toxicity
of crosslinking reagents. In the ionic gelation method, chitosan is dissolved in aqueous
acidic solution to obtain the cation of chitosan. This solution is then added dropwise
under constant stirring to polyanionic tripolyphosphate solution. Due to the complexation
between oppositely charged species, chitosan undergoes ionic gelation and precipitates to
form spherical particles. Although this method is simple, environmental friendly and easy
for mass production, nanoparticles formed by this technique have poor mechanical
strength.
The microemulsion method cross-links the amine groups of chitosan with aldehydes. In
this method, a water-in-oil emulsion is prepared by dispersing chitosan aqueous solution
in the oil phase. Aqueous droplets are stabilized by adding surfactant. The chitosan in the
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stable emulsion is cross-linked by cross-linking agent such as glutaraldehyde. Crosslinked nanoparticle are filtered and washed with n-hexan

[42,43]

. Particle size of the

nanoparticles is controlled by the size of aqueous droplets, the amount of cross-linking
agent and the speed of stirring during the formation of emulsion

[43]

. The microemulsion

method involves long processing time as well as use of harsh cross-linking agents. One
hundred percent removal of the un-reacted crosslinking agent is difficult.
The precipitation technique utilizes the physicochemical property of chitosan. Chitosan is
soluble in acidic medium. Chitosan polymer in the acidic medium will precipitate when it
comes in contact with alkaline medium. Nanoparticles are produced by blowing chitosan
solution into an alkaline medium using a compressed air nozzle to form chitosan droplets
[44]

. Separation and purification of nanoparticles was done by centrifugation followed by

successive washing. The size of obtained nanoparticles is controlled by the compressed
air pressure and spray-nozzle diameter. The speed of drug release is determined by crosslinking agents.
Reverse micellar technique can produce ultrafine polymeric nanoparticles with narrow
size distribution

[45,46]

. Reverse micelles are thermodynamically stable liquid mixtures of

water, oil and surfactant. Because the size of the reverse micellar droplets is usually ultra
fine and highly mono-dispersed, nanoparticles prepared by this method always possess a
narrow size distribution. In reverse micellar method, the surfactant is first dissolved in an
organic solvent, aqueous drug containing chitosan solution is added with constant
vortexing to avoid any turbidity. To this clear solution, a cross-linking agent is added
with constant stirring. The organic solvent is then evaporated to obtain the dry mass. The
material is dispersed in water and the surfactant is precipitated by adding suitable salt to
the aqueous solution. The precipitated surfactant is separated by centrifugation, and
nanoparticles remains in supernatant solution. Nanoparticles can be separated from the
supernatant by dialysis and lyophilization.
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2.1.1.3

Other polymeric nanoparticles

Besides natural biodegradable polymers such as gelatine and chitosan, some synthetic
polymers such as PLGA and PLA also show superb safety and biocompatibility. Those
polymers are also suitable to be made into nanoparticles.
PLGA (poly-D,L-lactide-co-glycolide) is a FDA approved polymer for therapeutic use in
humans. It undergoes hydrolysis in the body to produce lactic acid and glycolic acid.
Since the two monomers are effectively metabolized by human body, there is very
minimal systemic toxicity associated with PLGA and its metabolites

[47]

. A variety of

techniques can be applied to produce PLGA nanoparticles, such as emulsification
interfacial deposition

[49]

and nanoprecipitation method

[50]

[48]

,

. As for the emulsification

method, PLGA polymers are dissolved in organic solvent, poured and separated in
aqueous phase having stabilizer and subsequently emulsified by homogenizer. The
interfacial deposition is based on spontaneous emulsification of the organic internal phase
containing the dissolved polymer into the aqueous external phase. PLGA is dissolved in a
water-miscible solvent first. This phase is then injected into a stirred aqueous solution
containing a stabilizer as a surfactant. The fast diffusion of the solvent causes polymer
deposition on the interface and formation of a colloidal suspension. In nanoprecipitation
method, organic solvent dissolved PLGA is added dropwise into continuously stirring
aqueous phase to form a micelle, organic phase is consequently removed under reduced
pressure.
Polylactic acid (PLA) is a biocompatible, biodegradable substance that is synthetically
derived from natural components. It has been used in surgical products such as
dissolvable stitches, bone screws and cosmetic treatment of scars and wrinkles. PLA is
degraded in the body to monomeric units of lactic acid, which is a natural intermediate in
carbohydrate metabolism. Similar to PLGA, PLA nanoparticles can be prepared by
emulsification [51,52], interfacial deposition [53] and nanoprecipitation method[54] .

14

2.1.1.4

Application of polymeric nanoparticles

Due to the advantages of polymeric nanoparticles such as stability, non-toxicity, and
biodegradability, they are widely studied as a protein / plasmid carrier and applied in the
field of non-viral gene delivery, controlled release and targeted delivery of proteins.
Polymeric nanoparticles can sometime supersede the long used viral vectors as a gene
delivery system. Compared to viral vectors, polymeric nanoparticles are relatively easy to
prepare, less immunogenic, and have no potential of virus recombination. In addition,
structurally modifying polymeric nanoparticles can adjust their delivery efficiencies.
Gelatin nanoparticle is an effective vector to achieve gene delivery

[55]

. Through surface

modification, some specific characteristics can be imparted to gelatine nanoparticles such
as prolonged in vivo circulation

[56]

and tumour targeting

[57]

. Nanoparticles made from

chitosan or chitosan derivatives also show efficient gene transfection [55, 58].
Targeted drug delivery can achieve a high therapeutic efficiency with minimum side
effects. By controlling the particle size or modifying particle surface properties,
polymeric nanoparticles can be made into targeted drug delivery systems. The surface
modicication could be accomplished through adjusting nanoparticles’ surface
physiochemical characteristics or grafting nanoparticles’ surface with ligands that can
bind specifically to target cells or tissues. For example, nanoparticles with hydrophilic
surface show prolonged residing time in circulation system

[57]

; antibody grafted

nanoparticles accumulate specifically to the cells where matching antigens are expressed
[59, 60]

.

Biodegradable polymers are also broadly investigated as controlled drug delivery system.
Those polymers undergo hydrolysis or enzyme digestion upon contacting with body
fluids, and generate biocompatible and metabolizable moieties that are eventually
removed from the body. Many reports suggest that the degradation rate of those polymers
can be controlled by changing their molecular weight, cross-linking degree and polymer
compositions [61].
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2.1.2 Inorganic nanoparticles
Drug release from biodegradable polymeric nanoparticles usually relies on the erosion of
the carriers. The drug release usually takes place immediately upon water contaction.
Such premature release of guest molecules sometimes presents a challenging problem.
For example, targeted delivery of antitumor drugs and gene requires minimum release
before nanoparticles reach the targeted cells or tissues. Such premature release is less
likely to happen if drugs are loaded into inorganic nanoparticles. Inorganic nanoparticles
also possess other properties that make them promising targeted or controlled delivery
systems. Such properties include stable structure, large surface area, rich functionality,
tunable pore sizes, well-defined surface properties as well as good biocompatibility.
Numerous researches have done in the development of inorganic nanoparticles drug
carriers

[62,63]

. Gold and silica nanoparticles are two of the most popular inorganic

nanoparticle drug carriers because of their low toxicity and reliable synthesis.

2.1.2.1

Gold nanoparticles

Gold nanoparticles (AuNPs) possess several unique features that make them ideal carriers
for drug delivery. AuNPs are essentially inert, non-toxic [64], and can be produced reliably
with particle sizes ranging from 1 nm to 150 nm

[64-66]

. The surface of AuNPs is readily

to be modified by functional groups such as thiols and amines

[64]

. The optical and

electronic features of AuNPs can be applied to control drug release [67]. Various moieties
such as oligonucleotides, proteins, and antibodies and be linked to AuNPs and deliveried
into living cells [68-70]. The release of those loaded moieties could be triggered by internal
changes in pH, glutathione levels

[71,72]

, or external exertion of light

[73]

.

Such

applications in drug delivery represent a new direction of AuNPs research that greatly
deviates from the more established use of AuNPs as labels for electron microscopy

[74]

.

Gold nanoparticles can be prepared by various techniques such as citrate reduction,
Brust-Schiffrin method and microemulsion.
Citrate reduction is the most conventional methods to synthesize AuNPs. It applies citric
acid to reduce HAuCl4 in water. The ratio of the HAuCl4, reducing agents can be varied
to obtain AuNPs of with different particle sizes (between 20 and 150 nm). This method is
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often used when a loose shell of ligands around the gold core is required to prepare
modified AuNPs [65].
Brust-Schiffrin method allows the facile synthesis of stable AuNPs of small size (1.55nm) and narrow size distribution. The obtained AuNPs can be repeatedly isolated and
re-dissolved in common organic solvents without irreversible aggregation. Furthermore,
the AnNPs can also be functionalized just as stable organic and molecular compounds.
The technique uses the thiol ligands that strongly bind gold due to the soft character of
both

Au

and

sulfur.

Specifically,

AuCl4

is

transferred

to

toluene

using

tetraoctylammonium bromide as the phase-transfer reagent and reduced by NaBH4 in the
presence of dodecanethiol

[75]

. The sizes of particles are in the range 1-3 nm. Larger

thiol/gold mole ratios or faster reducing agents addition gives smaller particle sizes.
The use of microemulsion technique involves a two-phase system with a surfactant that
causes the formation of the microemulsion. The microemulsion helps to maintaining a
favorable microenvironment for the AnNPs synthesis and extract metal ions from
aqueous phase to organic phase. An example of this method is the synthesis of
dodecanethiol capped AuNPs within a microemulsion of diethyl ether/aerosol-OT/water.
The reduction of gold chloride in the presence of dodecanethiol results in the formation
of stable, organically soluble nanoparticles of 4nm average diameter [76].

2.1.2.2

Silica nanoparticles

Silica nanoparticles are comprised of a honeycomb-like porous structure with hundreds
of empty channels that are able to encapsulate relatively large amounts of bioactive
molecules. Silica nanoparticles possess several unique properties, such as high surface
area, large pore volume, tunable pore size with a narrow size distribution, and good
stability. Such properties make them promising carriers for controlled or targeted drug
delivery.
The synthesis of silica nanoparticles is developed on the technique found by Mobil
researchers. Specifically, tetraethyl orthosilicate (TEOS) is used as a silica source, a
cationic surfactant cetyltrimethylammonium bromide (CTAB) is used as a structure
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directing agent, water is used as solvent, and sodium hydroxide is used as catalyst

[77]

.

The template surfactant (CTAB) is removed by solvent extraction to generate pores. This
technique is base on the formation of liquid-crystalline mesophases of surfactants that
serve as templates for the in situ polymerization of orthosilicic acid. The synthesis can be
performed either in acidic or basic conditions, and the source of silica can be fumed
silica, sodium silicate, or tetra-alkyl oxide of silane [62].
Surface modification can impart silica nanoparticles with special properties to meet
different requirements. Co-condensation and grafting
modification

methods

for

silica

nanoparticles.

[78]

In

are two most applied

co-condensation

method,

organoalkoxysilane is introduced to the basic, aqueous CTAB and TEOS solution, and
surface modified silica nanoparticles are directly synthesized. Grafting is commonly
carried out by silylating free (≡SiOH) and geminal silanol (=Si(OH)2) groups on the
surface of silica nanoparticles. This reaction is performed on surfactant-removed
mesoporous silica in nonpolar anhydrous solvents to avoid a reaction of the organosilanes
with anything but the silica material.

2.1.2.3
2.1.2.3.1

Application of inorganic nanoparticles
Gold nanoparticles

Glutathione mediated delivery: The intracellular glutathione concentration is
substantially higher than its extracellular levels

[79-82]

. The phenomenon provides a

mechanism for selective intracellular drug delivery with AuNPs. The AuNPs carrier is
modified by a mixed monolayer composed of cationic ligands and model drugs. The
ligands generate a cationic surface to enhance cellular uptake. Once the carriers entered
cells, the concentrated glutathione in the cells would replace the loaded drugs from the
AuNPs [83].
Through sulfur-gold bonds, 6-mercaptopurine-9-β-D-ribofuranoside (6-MPR) can be
loaded to the surfaces of AuNPs

[84]

. Compared to free drug, the anti-proliferative effect

of 6-MPR is significantly enhanced by its AuNPs carrier. The enhanced anti-proliferation
effect can be explained by two cooperative mechanisms. First, 6-MPR loaded AuNPs
could be endocytosed and transferred to the lysosomes, the sulfur-gold bonds are severed
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in the acidic environment of lysosomes. Second, sulfur containing biomolecules such as
glutathione and cysteine, can simply replace 6-MPR from the Au surface.
AuNPs can also be modified with multiple moieties. A targeted AuNPs is obtained by
functionalizing AuNPs with 1) cyclodextrin (SH-CD) to encapsulate drugs, 2) antiepidermal growth factor receptor (anti-EGFR) antibody as a targeting moiety, and 3)
PEG as an anti-fouling shell. Rhodamine B is used as model drug

[85]

. Compared with

regular cell lines, internalization and drug release of this AuNPs are faster in cells with
higher glutathione concentration and EGFR surface expression.
PEG mediated delivery: Polyethylene glycol (PEG) has been approved for human
intravenous application. The surface of PEG modified AuNPs has a PEG layer that
inhibits colloid aggregation
conditions

[88,89]

[86,87]

and resists protein adsorption in physiological

. Drugs on the nanoparticles could be shielded from endocytosis of the

reticuloendothelial system

[90]

. Therefore, the circulation time of nanoparticles are

extended. Such drug vectors can preferentially accumulate in tumor sites

[90]

. Tumor

necrosis factor (TNF) is loaded into such AuNPs and the obtained TNF-PEG-AuNPs
shows a targeted TNF delivery into solid tumors [91].
AuNPs modified with a monolayer of folate-conjugated poly (L-aspartate-doxorubicin)b-poly(ethylene glycol) copolymer (Au-P(LA-DOX)-b-PEG-OH/FA) can work as a
tumor targeted drug carrier

[92]

. The Au-P(LA-DOX)-b-PEG-OH/FA consists of an Au

core, a hydrophobic poly(L-aspartate-doxorubicin)

inner shell, and a hydrophilic

poly(ethylene glycol) and folate-conjugated poly(ethylene glycol) outer shell (PEGOH/FA). Tumor cell endocytosis of the nanoparticles is facilitated by the folate receptors,
are highly expressed on the surface of tumor cells. The release of doxorubicin (DOX)
from the modified AuNPs is promoted by acidic environment in tumor cells.
Other ligands mediated delivery: Various other ligands are also able to stabilize and
direct AuNPs to targets. Chitosan modified AuNPs are applied to deliver insulin. This
new system showes a significant blood glucose lowering effect and a noticeable
improvement in the cell uptake than the oral and nasal administered insulin [93].
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Kamat’s group attached a light-sensitive and conformation-changing molecule,
spyropyran, to surface of AuNPs. Amino acid is loaded to the nanoparticles by forming a
complex with spyropyran. When spyropyran is irradiated by ultraviolet light, it undergoes
a conformation change from an open form to a closed form, which triggers the release of
amino acid [94].

2.1.2.3.2

Silica nanoparticles

Drugy delivery controlled by morphology: Due to the high surface areas and pore
volumes of silica nanoparticles, guest molecules are able to be simply adsorbed on the
porous surface or into the pores. Release of the loaded drug is controlled either by the
size or the morphology of the pores. Silica nanoparticles with large pores (5nm) can host
small membrane-impermeable proteins, such as cytochrome c, and release them under
physiological conditions

[96]

. These silica nanoparticles serve as efficient transmembrane

carriers to deliver cytochrome c into HeLa cells.
Drug delivery controlled by surface modification: Surface modified silica
nanoparticles can be use for DNA delivery. Thiol groups modified silica nanoparticles
are covalently attached to PAMAM dendrimers. The G2-PAMAM capped silica
nanoparticles are used to complex with plasmid DNA. The complex protects the plasmid
DNA from enzymatic cleavage. This nano gene carrier shows better transfection
efficiency than most commercial transfection reagents [97].

2.2 Enzyme immobilization with nanomaterials
Biocatalysis, a green, sustainable technology for chemistry industry, commonly uses
enzymes as highly active and selective catalysts. Most enzymes operate at mild
temperature, neutral aqueous solutions, and in the absence of substrate functional-group
protection

[98]

. Additionally, enzymes catalyzed reactions generally tolerate structurally

diverse substrates, produce highly stereo-, enantio- and regiochemically defined products,
and usually generate waste streams suitable for municipal sewers

[99]

. In practical

production, an enzyme can be used alone, in combination with other enzymes, or with
non-biological reagents. With the improvement of biotechnology such as protein
engineering

[100,101]

, gene synthesis, and bioinformatics tools

[102]

, engineered enzymes
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that meet the specific requirements of a given process can be produced on a large scale.
Those engineered enzymes usually possess special properties such as superb stability
against temperature or organic solvents, and ability to catalyze non-natural reactions [103].
However, despite the fact that over 3,000 enzymes have been identified, only a little
proportion of them is exploited for chemistry industry [98].
The economic feasibility of an enzyme catalyzed process is determined by several major
factors: 1) the type of enzyme to be used, 2) the stability of the selects enzymes and 3)
the reactor and hardware configurations

[104]

. Many expensive enzymes could not be

applied in industry unless they were made recyclable and reusable. Although free
enzymes can be recycled with coupled reaction and immobilized cofactor
techniques require costly modification of current standard reactors

[105]

[106]

, those

. Enzyme

immobilization may make the application of high cost enzymes in industry economically
feasible for many reasons: 1) Immobilized enzymes are convenient to be recycled for
continuous utilization. 2) Immobilization usually enhances enzyme stability under storage
and operational conditions. 3) Immobilization enables enzymes to be used in a packedbed or fluidized-bed reactor

[106]

. 4) Enzyme immobilization helps to reduce protein

contamination of the product.
Enzymes can be immobilized to a substrate via a variety of techniques such as noncovalent adsorption, covalent attachment, polymeric entrapment and cross-linking

[107]

.

However, all these approaches are a compromise between maintaining high catalytic
activity and achieving the advantages of immobilization

[108]

.

The performance of

immobilized enzymes depends on the properties of supporting materials such as material
composition and structure. Nonporous substrates have minimum diffusion limitation, but
their enzyme loadings are usually low. On the other hand, porous materials are
characterized by higher enzyme loading, but greater diffusion limitation than nonporous
enzyme support. The large surface area and small size of nanomaterials make them ideal
enzyme supporters for bio-catalysis. The larger surface area leads to higher enzyme
loading per unit mass, and the small size shortens diffusion path of reactants and leads to
much reduced mass-transfer resistance

[109]

. Moreover, Attaching to nanomaterials can
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significantly stabilize some free enzymes

[108,109]

.

The supporting nanomaterials for

enzyme immobilization include nanoparticles and nanowires/nanotubes.

2.2.1 Application of nanoparticles for enzyme immobilization
Nanoparticles made from numerous inorganic materials, such as calcium carbonate,
Fe3O4, and silica, have been applied to support enzyme immobilization. Calcium
carbonate nanoparticles are exploited to immobilize glucose oxidase to detect glucose.
Immobilized glucose oxidase exhibit a marked improvement in thermal stability
compared to other inorganic glucose oxidase host matrixes. The system shows a rapid
response, a wide linear range, a high sensitivity, as well as a good operational and storage
stability

[110]

. Fe3O4 magnetic nanoparticles are used to immobilize yeast alcohol

dehydrogenase (YADH) via covalent binding. Compared to the free enzyme, the
immobilized enzyme retains 60% activity and shows a great increase in stability and
activity

[111]

. Cofactor NAD(H) covalently attached to silica nanoparticles is able to

coordinate with other enzymes immobilized on the same particles. Such coordination
enables multistep bio-transformations

[112]

. Specifically, silica nanoparticle-attached

glutamate dehydrogenase (GLDH), lactate dehydrogenase (LDH) and NAD(H) are
applied to catalyze the coupled reactions for production of α-ketoglutarate and lactate
with the cofactor regenerated within the reaction cycle. The nanoparticles enzyme
carriers provide effective interactions among the catalytic components, and thus realize a
dynamic shuttling of the particle-supported cofactor between the two enzymes to keep the
reaction cycles continuing.
Despite the popularity of nanoparticle based enzyme supporters, their indigenous
disadvantages limit their broad application: due to their small size and high surface
energy, they are unstable over long storage. Moreover, if dispersed, those nanoparticles
are impossible to be recycled with current standard reactors [113].

2.2.2 Application of nanorods for enzyme immobilization
Nanorods are nano sized rods/wires/ tubes manufactured or grown onto the surface of
their substrates. The premise of using nanrodss for immobilization is to reduce diffusion
limitations and maximize the functional surface area to increase enzyme loading [114].
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Glucose oxidase (GOx) can be immobilized to ZnO nanotubes[115] or gold nanorods[115]
to work as a glucose sensor. The substrates of such nanorods/nanotubes can be metallic
or cellulose acetate membrane. Immobilization does not alter the native conformation and
activity of GOx. The obtained glucose sensor shows superb sensitivity, linear range, antiinterference ability and long-term stability.
Alcohol-dehydrogenase

(ADH)

functionalized

nanowires

can

work

as

a

bioelectrocatalytic system for enzymatic transformations of ethanol. Specifically, ADH is
functionalized to three-segment (Ni-Au-Ni) nanowires, the nanowires are integrated with
carbon nanotubes (CNT) modified amperometric to form a microsystem. The presence of
the ethanol substrate and NAD+ cofactor will switch the orientation of the nanowires
from vertical to horizontal and bring ADH and its NADH product to the CNT film. This
promotes the electrocatalytic detection of NADH and the regeneration of NAD+ essential
for enabling the continuous bioelectrocatalytic turnover. Such microsystem has been used
to develop a biosensor for simultaneous detection of methanol and ethanol [116].

2.3 Summary
Despite their strong activities, high catalytic specificities, and commercial availability,
proteins and enzymes still face several major barriers in their way to broad industrial
application. The most significant one of the barriers is their instability.
Loading or immobilizing proteins or enzymes into nanoparticles can protect them from
premature degradation, enhance their stability and prolong their activities. Lots of
protein-loaded nanoparticles have been commercialized for pharmaceutical application.
As for the biocatalysis, the small particle size of emzyme functionalized nanoparticles
brings a problem of efficient enzyme recycling with current standard reactors. Compared
to other enzyme immobilization supporters, nanorods not only keep the advantages of
nanoparticles as enzyme supports, but also economically feasible for recycling in
standard reactors. Such technology is a promising method to produce stable and high
efficient biocatalysts.
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Chapter 3
Materials and Experimental Methods
3.1 Materials
2-Aminoethyl

methacrylate

hydrochloride

(AEMA),

2,2-Dimethoxy-2-

Phenylacetophenone (DMPA), 2-Hydroxyethyl Methacrylate (HEMA), 4-Nitrophenyl
acetate, Acetic acid (≥99.5%), Albumin bovine serum, Ammonium hydroxide (A.C.S
reagent, NH3 content 28-30%), Calcium chloride (93.0%), Carbonic anhydrase (from
bovine erythrocytes), Chitosan (medium molecular weight), Cyclohexane (A.C.S grade,
≥99%), Dimethyl Sulfoxide (DMSO, ≥99.9%), ethylene glycol dimethylacrylate
(EGDMA), Gelatin (from porcine skin, type A), Glutaraldehyde solution, Grade I (25%),
Gold (III) chloride trihydrate, Hydrochloric acid (36.5-38.0%), Heparin disaccharide I-A
sodium salt, Hexamethylenetetramine, Hexyl alcohol (regent grade, 98%), Hydrochloric
acid (36.5-38.0%), Phenolphthalein, SigmaFast protease inhibitor tablets, Sodium
Chloride, Sodium citrate tribasic dihydrate (ACS reagent 99.0%), Sodium hydroxide,
Sodium tripolyphosphate (85%), Tetraethyl orthosilicate (regent grade, 98%),
Tris(hydroxymethyl) aminomethane (Tris), Triton X100, zinc acetate dehydrate (99.9%),
zinc nitrate hexahydrate (98%) were purchased from Sigma-Aldrich. Acetone (regent
grade) and Ethyl alcohol (95%) was obtained from Caledon (ON, Canada) and
Commercial Alcohols (ON, Canada) respectively. BCA protein assay kit was bought
from iNtRON Biotechnology (South Korea), Omnipur PBS tablet (phosphate buffer
saline, pH7.3-7.5) was purchased from EMD Chemical (USA). Recombinant human
basic fibroblast growth factor (bFGF) was purchased from Invitrogen (CA, USA).
Human bFGF ELISA kit was obtained from RayBiotech Inc. (GA, USA).
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3.2 Experimental Methods
3.2.1 Synthesis of gold nanoparticles
12 mg Gold (III) chloride trihydrate was dissolved in 50 mL distilled water to reach a
concentration of 0.1 mmol/L. 1.14 g Sodium citrate tribasic dihydrate was dissolved in
100 mL of distilled water with the concentration of 38.8 mmol/L. Gold (III) chloride
trihydrate solution was heated to boil under constant stirring. 5.5 mL Sodium citrate
tribasic solution was added to the boiling Gold (III) chloride trihydrate solution, stirring
was continued for 15 mins. The color of the solution changed from yellow to dark blue to
purple and finally to red. Once the color turned to red, heating was stopped and the
solution was cooled down to room temperature, and 0.1 mM gold nanoparticles (AuNP)
were thus obtained.

3.2.2 Labelling BSA with gold nanopartilces
To label bovine serum albumin (BSA) with AuNP, the least BSA to AuNP ratio which
keeps the AuNP resistant to aggregration should be found first. Different amount of 0.4
mg/mL BSA solution were mixed with 2 mL AuNP and diluted to 5 mL to make series
solutions with different BSA to AuNP ratio. The series solutions were incubated in dark
for 30 mins. Afterward, 1 mL of 2 mol/L sodium chloride solution was added to the
series solutions and the mixtures were store at room temperature for 1 hour. After 1 hour,
the color change of the series solutions was recorded. Optimal BSA to AuNP ratio was
determined by selecting the lowest ratio that can keep the color (surface plasma
resonance) of AuNP consistent.
According to the optimal ratio of 40 µg BSA to 1 mL AuNP, the labeling was carried out
by dissolving 10 mg BSA in 25 mL distilled water to the concentration of 0.4 mg/mL. 0.1
mL BSA solution was mixed with 1 mL AuNP and the mixture was incubated in
darkness for 30 mins. The UV-Vis absorptions of BSA, AuNP, AuNP labeled BSA
(BSA-AuNP) and BSA-AuNP released from gelatin microspheres were scanned from
400 nm to 800 nm.
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3.2.3 Characterization of AuNP labeled BSA (BSA-AuNP)
3.2.3.1

UV-Vis spectrum of BSA-AuNP

Different amount of 0.4 mg/mL BSA solution were mixed with 2 mL AuNP and diluted
to 5 mL to make series of BSA-AuNP solutions with different BSA to AuNP ratios. After
incubation in dark for 30 mins, their UV-Vis absorption was scanned from 200 nm to 800
nm.

3.2.3.2

Calibration curve of BSA-AuNP

1 mmol/L BSA-AuNP was diluted to 0.5, 0.25, 0.125, 0.0625 and 0.03125 mmol/L series
solutions with water. UV spectra of the series solutions were obtained by scanning them
from 200 nm to 800 nm. Using the absorption values of series solutions at their λmax as ycoordinates and concentrations of BSA-AuNP as x-coordinates, linear regression was
made to get equation of the calibration curve.

3.2.3.3

TEM observation of BSA-AuNP

The geometrical characteristics of BSA-AuNP were examined using a Phillips CM10
transmission electronic microscopy (TEM). TEM samples were prepared by placing a
drop of BSA-AuNP solution directly on a carbon coated copper grid (200 mesh). The
sample was air dried overnight before TEM examination.

3.2.3.4

FTIR spectra of BSA, AuNP and BSA-AuNP

Fourier transform infrared (FTIR) was utilized to study the interaction between AuNP
and BSA. 250 mg BSA was dissolved into 25 mL AuNP. AuNP and BSA-AuNP
powders were obtained by lyophilization. BSA-AuNP, BSA and AuNP were scanned by
FTIR in the range of 500–4000 cm-1 with a 1 cm-1 resolution. The instrument used air as
background.

3.2.3.5

Raman spectra of BSA, AuNP and BSA-AuNP

Raman was also applied to study the interaction of AuNP with BSA. 250 mg BSA was
dissolved into 25 mL AuNP. AuNP, BSA-AuNP powders were obtained by
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lyophilization. BSA-AuNP, BSA and AuNP were scanned by Raman in the range of
100–2000 cm-1 with a 2 cm-1 resolution.

3.2.4 Incorporation of BSA-AuNP into gelatin microspheres
1.5 g gelatin was dissolved in 15 mL distilled water to a concentration of 10% (wt/vol) at
50°C. 3 mL span 80 was added to 150 mL liquid paraffin as the oil phase. The oil phase
was mixed homogeneously and heated to 50°C. Different amount of glutaraldehyde (20,
30 µL) was added into the 10% gelatin solution and stired for 30 seconds. The gelatin
solution was slowly poured into the oil phase to form the gelatin microspheres. To
crosslink the gelatin microspheres with glutaraldehyde, the microspheres were first
stirred at 50°C for different time (30, 45 mins), then at room temperature till the total
strring and reaction time reached 60 mins. After reaction, 100 mL acetone was added to
the oil phase under vigorous stir, gelatin microspheres was dehydrated by the acetone and
precipitated from the the oil phase. The precipitated gelatin microspheres were separated
from solution with filter paper. The precipitate was washed with 25 mL acetone for three
times by sonication (to re-disperse the microspheres in washing media) following
centrifuging (5,500 rpm, 10 mins, to precipitate microspheres from washing media). The
washed microspheres were air dried at room temperature overnight. The process to
produce gelatin microsphere is shown in Figure 3.1.

Figure 3.1 Preparation of gelatin microspheres
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BSA-AuNP was added to dry gelatin microspheres at a ratio of 4mL BSA-AuNP to 0.4 g
dried gelatin microspheres. The mixture was first frozen with liquid nitrogen. Afterward,
the frozen samples were lyophilized with a VIRTIS Sentry Freeze Dryer (SP Scientific,
USA) overnight. In every 1 g of the obtained gelatin microspheres, there was 10 µM
BSA-AuNP and 400 µg BSA, respectively.

3.2.5 BSA -AuNP release from gelatin microspheres
0.4 g BSA-AuNP loaded gelatin microspheres and 0.4 g plain gelatin microspheres were
mixed with 40 mL deionized water to work as sample and reference. The release test was
carried out at 37°C. At 1, 2, 3, 4, 6, 8, 12, 24 hours after the release, 1 mL release
medium was taken out from the sample and reference and kept at 4°C. Before testing, all
samples were first heated at 37°C to be liquefied and centrifuged at 5,000 rpm for 5 mins
to get the supernatant. 150 µL supernatant of each sample was put into a well a 96-well
plate. The absorption of the samples was tested with a plate reader at 525 nm. Using the
percentage of released BSA-AuNP to its initial drug load as y-coordinates, and release
time as x-coordinates, BSA-AuNP release profiles from different carriers were drawn.

3.2.6 Gelatin dissolution from gelatin microspheres
Plain gelatin samples taken at Part 3.2.5 were used to test the gelatin dissolution in the
release media. Before testing, all samples were first taken from 4°C refrigerator and
heated at 37°C to be liquefied. Afterwards, the samples were centrifuged at 5,000 rpm for
5 mins to get the supernatant. 25 µL supernatant of each sample was diluted 50 times
with deionized water. Protein concentration in the diluted samples was tested with a BCA
protein assay kit. Using gelatin concentrations as y-coordinate and release time as xcoordinate, dissolution profile of gelatin microspheres was drawn.

3.2.7 Synthesis of ZnO nanorods (Contributed by Dr. Yi Cheng)
Seed solution was made by dissolving zinc acetate in 100 mL ethanol to a concentration
of 0.01 mol/L. The seed solution was dropped on glass chips and the seed layer was
heated at 90°C for 1 hour. After heating, the ZnO seeds coated glass chip was immersed
in 200 mL aqueous solution containing 0.025 mol/L zinc nitrate and 0.025 mol/L
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hexamethylenetetramine (HMTA) and the solution was heated at 90°C for another 3 h.
The final grown film was rinsed with deionized water and dried at room temperature.

3.2.8 Immobilization of CA on ZnO nanorods
A reversible denaturation process [1] was applied to immobilize carbonic anhydrase (CA)
on the ZnO nanorods.

CA was dissolved in Tris-HCl buffer (0.05 mol/L) to the

concentration of 1.25 mg/mL. The solution was first treated at 60°C for 30 mins,
afterwards, one 2.2×2.2 cm glass chip grown with ZnO nanorods was immersed into 3
mL pretreated CA solution and incubate together at 60°C for predetermined time. After
the incubation, the mixture was removed to 4°C and incubated for another 24 hours to get
the CA immobilized ZnO nanorods. The ZnO nanorods chip was removed from the
solution and rinsed with 1mL Tris-HCl buffer (pH 8.0, 0.05 mol/L) for 3 times.

3.2.9 Characterization of ZnO and CA-ZnO
The morphology of the aligned ZnO nanorods was studied by Hitachi 3400S Scanning
Electron Microscopy (SEM). (Contributed by Dr. Yi Cheng)
Fourier transform infrared (FTIR) was utilized to study the interaction between ZnO and
CA. 10 mg CA was first dissolved into 3 mL pH 8.0 Tris-HCl buffer (0.05 mol/L),
aftwewards, 10 mg ZnO nanorods were mixed with the CA solution and the mixture was
lyophilized. CA, ZnO nanorods and ZnO nanorods immobilized with CA (CA-ZnO)
scanned by FTIR in the range of 750–4000 cm-1 with a 1 cm-1 resolution. The instrument
used air as background.

3.2.10 Activity analysis of immobilized CA
CA concentration was determined by measuring its absorbance at 280 nm. An extinction
coefficient of 1.83 (mg/mL protein)-1 cm-1 was used to relate the absorption value to CA
concentration [1].
The activity of immobilized CA was analyzed by measuring the reaction speed of CA
catalyzed 4-nitrophenyl acetate hydrolysis

[2]

. The hydrolysis of 4-nitrophenyl was

measured by monitoring the appearance of 4-nitrophenolate anion at 410 nm. More
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specifically, 4-nitrophenyl acetate was dissolved in acetonitrile to get a 0.005 mol/L stock
solution. Assay solution was made by diluting stock solution with water at ratio of 3/17
(v/v). CA immobilized ZnO chip was added to the assay solution. At predetermined time,
the absorption of the assay solution was measured at 410 nm.

3.2.11 Application of immobilized CA for CO2 capture
CO2 saturated water was first made by pumping CO2 into deionized water till the pH
value of the deionized water gets stable at around 3.9. Immobilized CA was immersed
into 100 mL of the CO2 saturated water as the tested sample, another 100 mL of the same
CO2 saturated water was used as reference. CO2 was continuously pumped into the two
solutions. The experimental setup is shown in Figure 3.2.

Figure 3.2 Experimental setup for applying immobilized CA in CO2 capture
At predetermined time, 10 mL sample was taken out from each solution and the H2CO3 in
each sample was determined by titrating with 0.05 mol/L NaOH. 0.5% phenolphthalein
ethanol solution was applied as the titration end point indicator. Comparing with the
reference, the excess H2CO3 in the sample was the CO2 sequestrated by the CA catalyzed
CO2 hydration.

3.2.12

Synthesis of bFGF loaded nanoparticles

3.2.12.1 Synthesis of bFGF loaded chitosan nanoparticles
Chitosan was first dissolved in 0.4% acetic acid water solution to reach a concentration of
0.5% (wt/vol). bFGF solution (containing 1μg bFGF and 5 μg Heparin) was first added to
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10 mL chitosan solution with stirring for 5 mins. Afterward, 10 mL 0.25% sodium
tripolyphosphate (TPP) solution (wt/vol) was added following the bFGF solution
dropwise under constant stirring. After 20 mins, the mixture was centrifuged at 8,500 rpm
for 10 mins to precipitate nanoparticles. The precipitates was washed with 10 mL water
for three times by a brief sonication (to re-disperse the nanoparticles in washing media) centrifuging (8,500 rpm, 10 mins, to precipitate nanoparticles from washing media).
After washing with water, the nanoparticles were washed with 20 mL ethyl alcohol once
with the same method and the final bFGF nanoparticles were dried at 4°C. The
illustration of the process is shown in Figure 3.3 [3].

Figure 3.3 Synthesis of chitosan nanoparticles

3.2.12.2 Synthesis of bFGF loaded silica nanoparticles
6.25 μL acetic acid was mixed with 100 mL distilled water to form a pH4 acidic solution.
7.5 mL cyclohexane, 1.8 mL hexyl alcohol and 1.8 mL Triton X100 were mixed
homogeneously as oil phase. Under constant stirring, 0.5 mL pH4 acidic solution was
added to the oil phase first. 15 mins later, 100 μL tetraethyl orthosilicate (TEOS) was
added as silica precursor. The mixture was stirred for 60 mins before 60 μL ammonium
hydroxide was added as catalyst of TEOS hydrolysis and condensation. bFGF solution
(containing 1 μg bFGF and 5 μg Heparin) was added to the solution 10 mins after the
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induction of ammonium hydroxide. The final mixture then underwent constant stirring
for another 24 hours.

Figure 3.4 Reactions of TEOS that form silica particles

Figure 3.5 Synthesis of silica nanoparticles

40

To separate the silica nanoparticles, 25 mL acetone was added to the mixture to break the
emulsion and silica nanoparticles were precipitated by centrifugation (8,500 rpm, 10
mins). The precipitant was washed with 20 mL ethyl alcohol / acetone (50/50) for three
times by first sonication (to re-dis perse the nanoparticles in washing media) and then
centrifuging (8,500 rpm, 10 mins, to precipitate nanoparticles from washing media).
The final bFGF nanoparticles were dried at 4°C. The reactions of TEOS that forms silica
nanoparticles are shown in Figure 3.4[4], and the illustration of silica nanoparticle
systhesis is shown in Figure 3.5.

3.2.13

Characterization of bFGF loaded nanoparticles

The geometrical characteristics of chitosan and silica nanoparticles were examined using
Phillips CM10 transmission electronic microscopy (TEM). TEM samples were prepared
by placing a drop of nanoparticles-acetone suspension directly on a carbon coated copper
grid (200 mesh). The sample was dried before TEM examination.

3.2.14

Incorporation of nanoparticles into HEMA hydrogel

30 mg AEMA and 15 mg DMPA were dissolved in 100 μL DMSO respectively. The
above AEMA and DMPA solutions were mixed homogeneously with 3 mL HEMA, 1
mL DMSO and 6 μL EGDMA as hydrogel presursor. To get the nanoparticle-HEMA
hydrogel composite, 20 mg chitosan nanopartilces or 5 mg silica nanoparticles was added
to 1 mL of the hydrogel presursor. The nanoprticle-hydrogel presursor was sonicated for
2 mins to resuspend the nanoparticles in the hydrogel precursor. Afterwards, nitrogen gas
was pumped into sonicated mixture for 10 mins to saturate it with this inert gas. The
nitrogen saturated mixture was dropped into the molds attached on cover glasses, and
radiated under UV at 325 nm for 20 mins and for photopolymerization. The resultant
nanoparticle-HEMA hydrogel composites were immersed in 95% overnight and peered
off from the molds the next day. The process of photopolymerization of HEMA hydrogel
is shown in Figure 3.6.
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Figure 3.6 Reactions of photopolymerization of HEMA hydrogel

3.2.15

bFGF stability in release medium

Release medium was prepared by dissolving one SigmaFast protease inhibitor tablet into
100mL pH7.4 phosphate buffer solution. The stability tests of bFGF in release media was
carried out by adding 500 μL bFGF standard solution (10,000 pg/mL) into 12.5 mL
release medium. The test was performed at 4°C without agitation. At predetermined time
points, 0.4mL sample was taken and stored at -20°C. bFGF concentration in the samples
were quantified by enzyme linked immunosorbent assay (ELISA) analysis.

3.2.16

bFGF release from nanoparticles and nanocomposites

Release medium was prepared by dissolving one SigmaFast protease inhibitor tablet into
100 mL pH7.4 phosphate buffer solution. Release test was carried out in 12.5 mL release
medium at 4°C without agitation. Dry nanoparticles (20 mg for chitosan and 5 mg for
silica) and one piece of nanopariticle-HEMA hydrogel were added to the release medium.
At appropriate time points, 0.4 mL sample was taken and stored at -20°C. bFGF
concentration in the samples were quantified by ELISA analysis.
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Chapter 4
Delivery of Gold Nanoparticles Labeled Protein
Gold nanoparticles (AuNP) possess several unique properties that make them a promising
protein label for the development of a colorimetric protein assay method. First, AuNP
show strong and stable red color because of their size-dependent surface plasmon
resonance [10]. Second, the surface of AuNP can be modified and stabilized with a variety
of ligands available in proteins, such as thiols, disulfides, phosphine, amine, and
carboxylate

[11]

. Those ligands, especially those with sulfer atoms, are able to interact

with gold in a way like covalent linking.
Colorimetric protein assay is a seires of low cost, reliable and broadly applied standard
protein quantification methods. Among them, Biuret, Bradford and Bicinchoninic acid
assay (BCA) methods are the most applied ones. The accuracy of colorimetric protein
assay is not independent of the sampl properties and environmental factors. Biuret
method is influenced by protein purity and association state
Bradford method vary according to the molecular weight

[3]

[2]

; the analytical results of

and structure

[4,5]

of target

protein; and the BCA method is prone to the interference of a wide variety of substances
such as glucose
[8,9]

[6]

, fructose, lactose

[7]

, dithiothreitol, glutathione and mercaptoethanol

.

The availability of multiple protein binding sites on AuNP and the strong nature of those
interactions might produce a protein-AuNP complex with stable particle size. The
protein-AuNP complex could be inert to the factors that interfere with the accuracy of
other colorimetric protein assay method. The stable protein-AuNP complex could
generate a steady surface plasma resonance that could be easily detected and utilized to
quantify protein-AuNP concentration.
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4.1 Results and Discussion
4.1.1 Labeling BSA with gold nanopartilces (AuNP)
The color change of series sample solutions with different BSA to AuNP ratios is shown
in Figure 4.1 and Table 4.1.

Figure 4.1 Change of BSA coated AuNP’s surface plasmon resonance (SPR)
absorption when contacting with sodium chloride (From left to right: BSA to AuNP
ratios are 50, 20, 0 µg/mL; aggregation of gold nanoparticles increases)
AuNP is stabilized by electrostatic stabilization which arises from a mutual repulsion
between neighboring AuNP that occurs as a result of the negative surface charge of the
citrate layer

[10]

. Once exposed to salt (sodium chloride, for example), the repulsive

interaction is screened and colloid aggregation is triggered

[11]

. Based on their size-

dependent surface plasmon resonance (SPR) absorption, AuNP demonstrates a color shift
from red to blue with increased aggregation, which can be seen in Figure 4.1. The
absorption of the BSA on the citrate-coated AuNP further stabilizes the colloidal gold
particles against aggregation

[10]

. Once in contact with salt, the partial coated AuNP is

aggregated at a lower level and shows a purple color, the totally coated AuNP keeps
stable and no change in their surface plasmon resonance is observed.
Table 4.1 Optimization the ratio of BSA to AuNP (1 mmol/L)
BSA / AuNP (µg/mL)
BSA / AuNP (µg/umol)
0.4mg/mL BSA added (µL)
Au NPs added (mL)
Water added to (mL)
Color change after 24 h

0
0
0
2
5
Blue

2
2
10
2
5
Blue

8
8
40
2
5
Purple

20
20
100
2
5
Purple

40
40
200
2
5
Red

50
50
250
2
5
Red
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From Table 4.1, one can observe that when using more than 40 µg BSA in 1 mL of
AuNP, the color (which represents the surface plasma resonance of gold nanoparticles) of
AuNP solutions remains consistent. The consistent color suggests that AuNP is protected
from aggregation. To increase the sensitivity of the testing, AuNP needs to be coated with
the minimum amount of BSA so that a fixed amount of AuNP can be used to test as little
BSA as possible. According to the results in table 4.1, at ratio of 40 µg BSA to 1 mL 1
mmol/L AuNP, AuNP labeled BSA (BSA-AuNP) can obtain a stable signal that ensures
the highest sensitivity. At the minimum ratio of 40 µg BSA to 1 mL 1mmol/L AuNP,
AuNP label generates a stable, repeatable and reliable UV-Vis absorption with a λmax at
525 nm.

4.1.2 UV-Vis spectra of BSA-AuNP
UV-Vis spectra of samples with various AuNP to BSA ratio are shown in Figure 4.2 and
Figure 4.3. The maximum absorption of all BSA-AuNP is at 525 nm. All the spectra
show a similar shape to the bare AuNP, which indicates that when BSA to AuNP
(1mmol/L) ratio is in the range of 0-50 µg/mL (weight/volume), BSA coating does not
alter the absorption pattern AuNP.

Figure 4.2 UV-Vis spectra of samples with BSA/Au NPs ratios of 0, 2, 8, 20, 40 and
50
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Figure 4.3 UV-Vis spectra of BSA, AuNP, BSA-AuNP and BSA-AuNP released from
gelatin microspheres
At the range of 400-800 nm, BSA does not have UV-Vis absorption, AuNP and BSAAuNP have similar absorption peak and λmax. Due to the absorption of dissolved gelatin,
the spectrum of BSA-AuNP released from gelatin microsphere is slightly different that of
BSA-AuNP; however, they share the same λmax. Due to the fact that BSA-AuNP can
provide a signal independent of BSA concentration and the gelatin microsphere
loading/releasing process, AuNP can be applied in this research as a stable and repeatable
protein label.

4.1.3 Calibration curve of BSA-AuNP
The UV-Vis absorption of the series BSA-AuNP is shown in Figure 4.4. Within the
concentration range of 0.03125 mM - 0.5 mM, the λmax keeps constant. Using the
absorption value of a series of solutions at 525nm as y-coordinate and concentration of
AuNP in BSA-AuNP as x-coordinate, linear regression is carried out and the equation of
the calibration curve is A = 1.15537C – 0.01244, with r2 of 0.99776.
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Figure 4.4 UV-Vis spectra of series BSA-AuNP with different AuNP concentrations
With a fixed ratio of BSA to AuNP, we can establish a quantitative relation of BSA
concentration to the absorption of AuNP. From the fact that the optimal ratio of BSA to
AuNP is 40 µg BSA to 1 mL AuNP (1 mmol/L), and that the detection limit of AuNP is
0.03125 mmol/L, we can obtain a detection limit of BSA using AuNP as label is 1.25
µg/mL.

4.1.4 TEM observation of BSA-AuNP
TEM micrograph of gold nanoparticles is shown in Figure 4.5. The nanoparticles are
ideal spheres with a particle size of 15±3.5 nm and a homogeneous particle size
distribution. The TEM micrograph of BSA-AuNP does not show any difference from
that of the bare AuNP.
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Figure 4.5 TEM micrograph of BSA-AuNP

4.1.5 FTIR spectra of BSA, AuNP and BSA-AuNP
Figure 4.6 shows the FTIR spectra of AuNP, BSA and BSA-AuNP.

Figure 4.6 FTIR spectra of BSA, AuNP and BSA-AuNP
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In all the three spectra, the wide band stretching from 3100 cm-1 to 3400 cm-1 is the O-H
and N-H stretching band. On the low wavenumber side of the O-H and N-H stretching
band in the spectrum of BSA and BSA-AuNP, there are some broad bands of medium
intensity. These are overtone and combination bands of lower wavenumber C-C
stretching and C-H bending vibration. These features are quite common in the spectra of
carboxyl group, which are abundant in BSA because of the large amount of aspartic and
glutamic residues in BSA molecule.
In the spectra of BSA and BSA-AuNP, the prominent bands at 1660 cm-1 can be assigned
to the C=O stretch of amide bonds in BSA. At the wavenumber of 1530 cm-1, there is
strong band in the spectrum of BSA and a visible shoulder at the spectrum of BSAAuNP. It is the result of in plane bend of N-H in secondary amides. The significant peak
at 1590 cm-1 and 1400 cm-1 in the spectrum of BSA-AuNP and AuNP are attributed to the
asymmetric and symmetric stretch of the carboxyl group in sodium citrate. The structure
of sodium citrate tribasic can be seen in Figure 4.7.

Figure 4.7 Structure of sodium citrate tribasic
In the spectrum of BSA, the band at 1450 cm-1 is caused by the C-N stretch of BSA. In all
the spectra, the bands at 1250 cm-1 with medium intensity can be assigned to the C-O
stretch of the carbonyl group in sodium citrate and BSA. In the spectra of BSA-AuNP
and AuNP, the bands at (1) 1100 cm-1, (2) 900 cm-1, (3) 840 cm-1, and (4) 620 cm-1
originates from the tertiary alcohol of sodium citrate tribasic. Those bands can be
assigned to (1) the C-C-O asymmetric stretch, (2) CH2-C-CH2 stretch, (3) C-C-O
symmetric stretch and (4) O-H out of plane bending, respectively [12].

4.1.6 Raman spectra of BSA, AuNP and BSA-AuNP
Raman spectra of AuNP, BSA and BSA-AuNP are shown in Figure 4.8.
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Figure 4.8 Raman spectra of BSA, AuNP and BSA-AuNP
In the spectrum of BSA, the amide-I vibration at 1665 cm-1 arises mainly from the ν-C=O
stretching vibration. The band in the range of 1440–1480 cm-1 is caused by the C-H3 and
C-H2 deformation vibrations from the side chains of different amino acids. The amide-III
is the combination of the NH bending and C-C stretching vibration in the region 12001350 cm-1 and skeletal stretching region near 850-1000 cm-1 [13]. The bands around 1000
and 1030 cm-1 are due to the out-of-phase stretching of benzene and pyrrole residues
The disulfide stretching vibration of solid BSA is represented by the band at 500 cm

[14]

.

-1 [15]

.

Significant differences can be observed between the two Raman spectra of BSA and BSA
adsorbed on gold nanoparticles. In the spectra of AuNP and BSA-AuNP, the bands at
1590-1600 cm-1 and 1420-1440 cm-1 can be assigned to the C=O stretching of
carboxylate and C-H2 deformation vibration. The bands at 1320 cm-1 and 960 cm-1 in the
spectrum of AuNP are generated from the carboxylate and skeletal stretching of sodium
citrate [16].
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Some information about the interaction of BSA to AuNP can be obtained by comparing
the spectra of BSA and BSA-AuNP.

After combinging with AuNP, the strong amide

band at 1530 cm-1 in the FTIR spectrum of BSA dissapears and merges with the band of
carboxylate group. Additionally, in the Raman spectra of BSA and BSA-AuNP, the
prominent amide band at 1665 cm-1 of BSA is absent in BSA-AuNP. Combining the two
facts, it could be inferred that the BSA interacts with AuNP through its amide bonds. The
amide bonds may not be the only force that binds BSA to AuNP. BSA exhibits positively
charged amino acid, such as lysine or histidinem, and therefore could be conjugated to
the negatively charged surface of AuNP through the electrostatic interaction

[17]

. The

presence of S-S stretching vibration of disulfide bridges in the spectrum of both BSA and
BSA-AuNP is a strong indicator that the disulfide bonds remain unbroken and the BSA
does not denature when adsorbed to AuNP.

4.1.7 Release profiles of BSA - AuNP from gelatin microspheres
The BSA-AuNP release profiles from gelatin microspheres synthesized with different
amounts of crosslinker (glutaraldehyde), 20µL and 30µL, respectively, are shown in
Figure 4.9.

Figure 4.9 BSA-AuNP release profiles from gelatin microspheres synthesized with
different amount of glutaraldehyde
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The release of BSA-AuNP has been monitored for 12 hours. The release of BSA-AuNP
decreases from 75% to 60% when the amount of crosslinker used in the synthesis
increases from 20µL to 30 µL, or 1.6% (mL/g) to 2.4% (mL/g).
Figure 4.10 shows the BSA-AuNP release profile from gelatin microspheres synthesized
at a fixed amount of crosslinker 2.4% (mL/g) and reaction temperature (50°C); but
different reaction time (t) of 30mins and 45mins, respectively.

Figure 4.10 BSA-AuNP release profiles from gelatin microspheres synthesized with
different amount of reaction time at 50°C
All the microspheres allow a sustained BSA-AuNP release up to 12 hours. The release
profiles get to a plateu phase when BSA-AuNP release reaches 60% and 50% at t =30
mins and 45 mins, respectively. BSA release from gelatin microspheres can be thus
detected by the SPR of gold nanoparticles.

4.1.8 Release mechanism
The rate-controlling mechanisms of drug release from hydrophilic matrices are polymer
dissolution (erosion) and diffusion of drug molecules across the polymer lay [18]. A semi-
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empirical equation has been used widely to differentiate the contributions of both
mechanisms [19, 20].

Where Mt is the amount of drug released at time t, M the amount of drug in dosage form,
Qt the fraction of drug released at t, n the diffusional exponent, and k the kinetic constant.
If diffusion dominates polymer erosion, the value of n would approach 0.5. On the other
hand, for erosion controlled formulations, n would approach the value of 1. Under a
mixed condition, the value of n falls in between 0.5 and 1 when both diffusion and
erosion occurs simultaneously.
The above formula can be transformed into the following formula. Using releasing value
BSA-AuNP as Mt/M, we can calculate the value of k and n by linear regression.

The results of the calculation and the concluded release mechanism of samples in part
4.1.7 are listed in Table 4.2.
Table 4.2 Release mechanism of BSA-AuNP from gelatin microspheres
Sample
BSA-AuNP-GM (20 µL)
BSA-AuNP-GM (30 µL)
BSA-AuNP-GM (30 mins)
BSA-AuNP-GM (45 mins)

n value
0.34
0.45
0.23
0.34

Release mechanism
Diffusion controlled release
Diffusion controlled release
Diffusion controlled release
Diffusion controlled release

Upon contacting with release media, the gelatin microspheres swell due to hydrolyzation,
and generate enlarged channels for drug release. BSA-AuNP can easily pass through
these enlarged channels and go into release media. The more crossliner used to synthesize
the gelatin microsphere, the more porous the scaffold and the narrower the channels will
be. Such smaller channels make the transportation of BSA-AuNP from inside
microspheres to release media slower and harder. Additionally, prolonged reaction time
of the crossliner with gelatin microspheres results in a gelatin scaffold with a higher
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crosslinking level and mechanical strength. Compared with the scaffold of less reacted
gelatin microspheres, this more crosslinked scaffold is harder to hydrolyze and less likely
to swell in release media. The channels that BSA-AuNP need to go to release media are
more narrow and elongated, and thus, BSA-AuNP release is slower.

4.1.9 Degradation of gelatin microspheres
To investigate the release mechanism of BSA-AuNP from gelatin microspheres, the
degradation ofgelatin microsphere was studied by testing gelatin concentration in release
medium. The profile of gelatin concentration-time is showed in Figure 4.11.

Figure 4.11 Degration profile of gelatin microsphere
Gelatin microspheres dissolve gradually. Figure 4.11 showes the concentration of gelatin
in the release medium increases from 1 mg/mL to 4 mg/mL. Gelatin dissolution reaches
at a plateau at the eighth hour of the release test. Such gelatin dissolution curve is in
coincidence with the BSA-AuNP release profiles. The results suggest AuNP is seep into
the scaffold of gelatin microsphere during the loading process. During release, AuNP at
the out layer of gelatin microspheres is released in a diffusion controlled pattern. At the
same time, the gelatin scaffold undergoes degradation.

The degradation of gelatin
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shortens the channels that in gelatin microspheres scaffold and facilitates the movement
of AuNP from gelatin to the release media. This scaffold degradation keeps the constant
release rate of BSA-AuNP from gelatin microsphere to release media.

4.2 Conclusions
A new AuNP assisted protein assay method was developed in the works introduced in
this chapter. AuNP was used to label a model protein, BSA. FTIR and Raman spectra
were carried out to study the interactions between BSA and AuNP. The results show that
BSA is incorporated onto AuNP through the interaction between gold and amide
functional groups. The surface plasma resonance (SPR) of AuNP labeled BSA (BSAAuNP) has been investigated, which is linearly to the AuNP concentration within the
range of 0.03125-0.5 mmol/L. The detection limit of BSA-AuNP is 1.25 µg/mL. The
release profile of BSA-AuNP from gelatin microspheres has been investigated through
testing the SPR of AuNP in the term of crosslinker and reaction time. It is found that
BSA-AuNP is released from its gelatin micro-carriers for 12 hours in a diffusion
controlled manner. The degradation of gelatin microspheres is compatible to the diffusion
of BSA-AuNP.
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Chapter 5
Enzyme Immobilization with Nanorods for CO2 Capture
Enzymes are highly active and selective catalysts usually applied in bio-catalysis, a green,
sustainable and environmentally friendly technology in the chemical industry. Over 3,000
enzymes were identified, however, only a very few of them have been employed in
industrial scale [1]. The factors that hold back the wide spread application of enzymes are
1) the high cost of most enzymes and 2) the difficulties in recycling them from standard
reactors [2].
Enzyme immobilization is an economically feasible way to use pricey enzymes.
Immobilization makes enzymes reusable for continuous utilization, enhances enzyme
stability and enables enzymes to be used in packed-bed or fluidized-bed reactors

[2]

.

When using regular immobilization supporters, the process of immobilization is a
compromise between maintaining high catalytic activity and achieving the advantages of
immobilization

[3]

. Nonporous substrates have a minimum diffusion limitation while

enzyme loadings are usually low. On the other hand, porous materials are characterized
by higher enzyme loading, but have greater diffusion limitations than nonporous enzyme
supporters.
The large surface area and small size of nanomaterials make them ideal enzyme
supporters for bio-catalysis. The large surface area leads to high enzyme loading per unit
mass, and the small size shortens the diffusion path of reactants and leads to reduced
mass-transfer resistance

[4]

. Moreover, attaching free enzymes to nanomaterials

significantly protects them from losing their activities [3,4].
Nanorods are a nanomaterial that can be easily separated and recycled in reactors
without aggregation

[5]

. Because of the superb biosafety and biocompatibility of zinc

oxide (ZnO), ZnO nanorods could be an ideal enzyme immobilization supporter [6]. The
activities of immobilized enzymes are unlikely to be interfered with by the ZnO nanorods.
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The isoelectric point (pI) of ZnO is 9.5, which is higher than most proteins’ pI. Proteins
can be incubated together with ZnO nanorods in buffers with a pH value between the pI
of proteins and ZnO. In such buffers, protein and ZnO are oppositely charged and the
protein can attach to ZnO nanorods surface via electrostatic interaction.
In this chapter, carbonic anhydrase (CA), an enzyme that is usually applied to enzyme
electrodes

[7]

and carbon dioxide sequestration

[8]

, is selected as the model enzyme. ZnO

nanorods are used as the enzyme immobilization supporter.

5.1 Results and Discussion
5.1.1 Immobilization of CA on ZnO nanorods
The UV spectra of CA water solution and 60 °C treated CA Tris-HCl buffer (pH7.5,
pH8.0) solutions are shown in Figure 5.1.

Figure 5.1 UV Spectra of CA in different immobilization buffers
The heating (60 °C) treatment and Tris-HCl buffer do not interfere with the spectrum of
CA. The maximum absorption of CA is at a wave length (λ) of 280 nm, where the UV
reading is a function of the concentration of CA. The CA absorption before and after
immobilization are collected using a UV-vis spectrometer to calculated the CA
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immobilization ratios. The calculated CA immobilization ratios are 0% (in water), 50%
± 0.5 (in pH7.5 Tris-HCl buffer), and 59% ± 0.6 (in pH8.0 Tris-HCl buffer), respectively.
According to a report

[9]

, the reversible denaturation process makes CA immobilize onto

the hydrophobic substrate via simple absorption. However, based on our experiment, the
pH value played a major role in the immobilization process. CA dissolved in water could
not immobilize onto ZnO nanorods. Meanwhile, when the pH value of immobilization
buffer increased from 7.5 to 8.0, the immobilization ratio of CA increased from to 50% to
about 60%. The isoelectric point (pI) of CA and ZnO are 6.7-7.9

[11]

and 9.5

[12]

,

respectively. In the pH 7.5 and pH 8.0 immobilization media, ZnO is positively charged
whereas CA is negaitively charged. The electrostatic interaction, which is generated from
oppositely charged CA and ZnO nanorods, may be the real force that causes the
absorption and immobilization of free CA onto ZnO nanorods.

5.1.2 Characterization of ZnO nanorods (Contributed by Dr. Yi Cheng)
The top view of SEM micrograph of ZnO nanorod on a glass substrate is shown in Figure
5.2 (a). ZnO nanrods grew densely and uniformly on the substrate surface. The average
diameter of the ZnO nanorods is 161±10 nm. The cross-sectional SEM iamge of ZnO
nanorod arrays is shown in Figure 5.2 (b). All nanorods are well-aligned on substrate
surface and their average height is approximately 2 µm.

Figure 5.2 SEM micrographs of ZnO nanorods. (a) Top and (b) Cross-sectional view
FTIR spectra of ZnO, CA and CA-ZnO are shown in Figure 5.3. ZnO does not show any
bands. The bands around 2400 cm-1 are the asymetric stretch of CO2.
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Figure 5.3 FTIR spectra of ZnO, CA and CA-ZnO
In the spectra of CA and Ca-ZnO, the wide bands stretching around 3250 cm-1 are the NH stretching band. The prominent bands at 1650 cm-1 can be assign to the C=O stretch of
amide bonds in CA; the other strong bands at the wavenumber of 1540 cm-1 is the result
of secondary amide N-H bending.
ZnO does not have IR absorption. The major bands of CA and CA-ZnO are originated
from the amide bonds of CA. Those major bands do not show significant variation after
CA immobization. From the result, it can be concluded that chemical interactions are
unlikely the forces that cause the CA immobilization. The FTIR analysis supports the
hypothesis that electrostatic interaction generated from oppositively charged CA and ZnO
results in the CA attachement on ZnO nanorods.

5.1.3 Activity of Immobilized CA
The UV-Vis absorption of 4-nitrophenolate anion in different samples along with time (t)
is shown in the Figure 5.4. In all three samples, absorption intensity and time are found to
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have a linear relationship. Liner regression is made to calculate the slopes of the UV-Vis
absorption, which represents the speed of the hydrolysis of 4-nitrophenyl acetate.

Figure 5.4 Hydrolysis of 4-nitrophenyl acetate catalyzed by different CA-ZnO
4-nitrophenolate anion, a greenish yellow compound with a strong absorption near
400nm, is the product of the hydrolysis of the colorless 4-nitrophenyl acetate
reaction is shown in Fig. 5.5.

Figure 5.5 CA catalyzed hydrolysis of 4-nitrophenyl acetate

[10]

, the
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The speed at which this hydrolysis product is produced represents the hydrolysis speed of
4-nitrophenyl acetate

[10]

. The faster the 4-nitrophenyl hydrolysis, the more active the

immobilized CA would be. As shown in Figure 5.3, plain ZnO nanorods were used as the
reference to evaluate the activity of immobilized CA on ZnO nanorods (CA-ZnO). 4nitrophenyl acetate underwent self- hydrolysis at a speed of 0.0012 without the presence
of CA. Much faster hydrolysis was observed in solutions with CA-ZnO (0.0027 for CAZnO produced in pH 7.5 and 0.0060 for CA-ZnO fabricated in pH 8.0). CA-ZnO
immobilized in pH8.0 buffer showed the highest catalitic activitiy. CA-ZnO activity is in
accordance with the CA immobilization ratio. The higher the CA immobilization ratio,
the more active the obtained CA-ZnO would be.

5.1.4 Immobilized CA for CO2 capture
The amount of CO2 captured by CA-ZnO at different time points is shown in Figure 5.6.

Figure 5.6 CO2 captured by CA-ZnO nanorods at different time points
Using one 2.2×2.2 cm CA-ZnO as a catalyst, the catalyzed reaction reached equilibrium
after 45 mins in 100 mL water, with the sequestration of 6 mmol CO2. The amount of
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captured CO2 was analyzed by titration. The series of chemical reactions involved in the
titration are shown as here:
In the reactor, CO2 reacts with H2O and forms carbonic acid.

During the titration process, carbonic acid reacts gradually with sodium hydroxide and

forms first sodium bicarbonate and then sodium carbonate.

Phenolphthalein, which changes from colorless to pink when environmental pH is higher
than 8.2, was applied to indicate the end point of the titration. At the end point, all H2CO3
reacts with NaOH and forms alkaline Na2CO3, the Na2CO3 makes the color of
phenolphthalein change from colorless to pink.

Figure 5.7 Reusability of three 2.2×2.2 cm CA-ZnO in 100 mL water
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To test the reusability of CA-ZnO, one CA-ZnO chip was used three times in 100 mL
water to catalyze the CO2 capture. Figure 5.7 shows the reusability of three 2.2×2.2 cm
CA-ZnO chips in 100 mL water.
In the first two times of test, despite the strong turbulence generated by pumping CO2
into water, CA-ZnO maintained a similar ability to catalyze the H2CO3 genaration.
During the third test, the H2CO3 genaration, which represented the CA catalytic ability,
dropped nearly 50%.
The possible reasons for the loss of CA activity are the erosion of the ZnO nanorod and
the dissociation of CA from ZnO nanorods. They are possibily associated with the
turbulence of reaction media. Further studies are needed to find a way to reduce the
turbulence generated by pumping CO2 into the reaction media while keeping a constant
CO2 input for the catalyzed reaction.

5.2 Conclusions
In this chapter, carbonic anhydrase (CA) was immobilized onto ZnO nanorods (ZnO) by
a reversible denaturation process

[9]

. The immobilization was performed in a Tris-HCl

buffer, and the immobilization ratio and the activity of immobilized CA were determined
by the pH of the buffer. At pH 8.0, about 60% of CA in the buffer could be immobilized
to the ZnO and the activity of CA is maintained. The CA immobilized ZnO nanorod (CAZnO) was used to catalyze the reaction of CO2 with water. Using CO2 saturated water as
reference, 6 mmol CO2 is captured in 100mL water by a 2.2×2.2 cm CA-ZnO chip with
0.75 mg CA. This CA-ZnO chip could be used twice while keeping its activity in
catalyzing the reaction of CO2 with water. At the third time of reuse, its active efficiency
reduces nearly 50%. Further studies are needed to improve the reusability of the CA-ZnO
chip.
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Chapter 6
Sustained Protein
Nanocomposites

Delivery

with

Nanoparticle-Hydrogel

In the pharmaceutical industry, nanoparticles are gaining popularity and many of them
have been put in the clinical trial and commercialization

[1,2]

. As a drug delivery system,

nanoparticles are able to modify fundamental properties of loaded drugs such as stability,
half-life, and immunogenicity; and significantly improve their therapeutic effects [3].
Proteins, especially those with short half lives, are usually incorporated into nanoparticles
in order to be protected from degradation

[4, 5]

. Due to the abundant moiteties absent in

proteins, the protein incorporation process is possibly caused by multiple proteinnanoparticle interactions, especially electrostatic forces and hydrogen bonds.
Although one of the main advantages of nanoparticles is their improved systematic
absorption, in some special cases, such systematic absorption should be preferably
avoided

[6]

. Skin wound healing is an example of such a case. Skin wound healing is a

process in which the skin tissue repairs itself after injury. A sustained topical application
of therapeutic agents such as epidermal growth factor

[7]

can significantly promote this

process.
Regular wound dressings such as hydrogel can be used to provide topical drug delivery to
wound beds. However, such wound dressings only demonstrate a very limited capacity to
retain the release of loaded drugs

[7, 8]

. Nanoparticle based drug delivery systems were

developed to provide a sustained drug release. These systems utilized PCL-PEG
copolymer

[9]

, chitosan

[10]

or multiple polymers

[11]

. However, due to the systematic

absorption at wound bed, these nanoparticles are unable to provide a prolonged topical
drug release without being immobilized into wound dressings.
In the research introduced in this chapter, to achieve a sustained topical drug release as
well as an effective wound bed protection, protein loaded nanoparticles were embedded
into HEMA hydrogel to form a new wound dressing. Basic fibroblast growth factor
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(bFGF), a proven protein to accelerate wound healing and tissue regeneration

[12]

, was

selected as the model protein for this new wound dressing.

6.1 Results and Discussion
6.1.1 Synthesis of bFGF loaded nanoparticles
TEM micrographs of chitosan and silica nanoparticles are shown in Figure 6.1. All of the
obtained nanoparticles are spherical in shape and their particle sizes are 50±35 nm and
30±6 nm for chitosan and silica nanoparticles respectively.

(a)

(b)

Figure 6.1 TEM micrographs of chitosan (a) and silica nanoparticles (b)
The nanoparticles were made by different methods and thus show diverse particle sizes
(chitosan > silica) and size distributions (chitosan > silica). Without using any organic
solvent, the chitosan nanoparticles were made in the most environmentally friendly way.
Chitosan is polycationic in acidic media (PKa 6.5) and can interact with negatively
charged tripolyphosphate ions. The interaction of chitosan with sodium tripolyphosphate
leads to the formation of crosslinked chitosan nanoparticles [13].
Silica nanoparticles are synthesized by the sol-gel process, which is widely applied to
produce silica and metallic nanoparticles at mild conditions

[14-16]

. This sol-gel process

involves hydrolysis and condensation of tetraethyl orthosilicate (TEOS) in the presence
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of ammonium hydroxide (NH4OH) as the catalyst. The hydrolysis of TEOS molecules
form silanol groups. The condensation between the silanol groups and ethoxy groups
creates siloxane bridges (Si-O-Si) that form entire silica structure.

6.1.2 Incorporation of nanoparticles into HEMA hydrogel
Poly-(2-hydroxyethyl methacrylate) (HEMA) is a low toxicity
material

[18]

[17]

, non-degradable

. HEMA is an ideal tissue engineering material due to its good mechanical

strength and elasticity [19]. However, HEMA lacks functional groups to which biological
molecules can be easily attached. Therefore, reactive comonomers, typically containing
carboxyl and amino groups, are incorporated in the material

[18]

. In this research, 2-

Aminoethyl Methacrylate (AEMA) was crosslinked to HEMA via ethylene glycol
dimethylacrylate (EGDMA) by UV light radiation. The resultant product imparted
HEMA with amino groups

[20]

. 2,2-Dimethoxy-2-Phenylacetophenone (DMPA) worked

as the photoinitiator.
All the monomers were first dissolved in DMSO. After all the monomers were mixed
homogeneous, nanoparticles were suspended in the solution of monomers to form a
suspension for photopolymerization. After the reaction, monomers were crosslinked
together to form a porous three dimensional scaffold. Nanoparticles were embedded in
the scaffold to reach a sustained local drug release without entering into circulation and
being absorbed by the system.

6.1.3 Stability of bFGF in release medium
The ratio of tested bFGF concentration to its original concentration Ci/C0 (Ci: bFGF
concentration in the sample which was taken at time i, C0: original bFGF concentration
380 pg/mL) represents its stability. The average values of Ci/C0 at different times are
shown in Figure 6.2.
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Figure 6.2 Stability of bFGF in release medium
The Ci/C0 values varies between 0.75 and 0.8, the Ci values do not show a tendency to
decrease with the increase of incubation time. The results suggest that bFGF is kept
stable in the release buffer within 350 hours. Since SigmaFast protease inhibitor - pH7.4
phosphate buffer solution can protect bFGF from degrading, it is a suitable medium to
test bFGF release from its carriers.

6.1.4 Release of bFGF from nanoparticles and nanocomposites
The release profiles of bFGF from chitosan, silica nanoparticles and nanoparticle-HEMA
nanocomposites are shown in Figure 6.3 and 6.4 respectively. The release of bFGF is
represented by the ratio of bFGF concentration at time i (Ci) to the its maximum
concentration (Cmax) .
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Figure 6.3 Release of bFGF from chitoan nanoparticles (CN) and chitosan
nanoparticle-HEMA nanocomposite (CN-HEMA)
Chitosan nanoparticles showed a 230 hours sustained bFGF release with a burst within
the first 8 hours. bFGF can be associated to chitosan nanoparticles in three different
ways: at the nanoparticle’s surface, in the core as a reversible complex, or in the core as
an irreversible complex

[21]

. bFGF release can be withheld by chitosan nanoparticles

because chitosan is generally insoluble in neutral solutions and most organic solvents [22].
The burst release was possibly a result of the detachment of bFGF from the
nanoparticles’ surface. The sustained release after the first 8 hours might result from the
separation of bFGF from its reversible complex with chitosan and the disintegration of
chitosan or bFGF- chitosan irreversible complex. bFGF release can be withheld by
chitosan because it is generally insoluble in neutral solutions and most organic solvents
[22]

.

bFGF release from CN-HEMA nanocomposite was faster than that of the chitosan
nanoparticles; in 50 hours, the release of bFGF reached maximum value. This
phenomenon was contradictory to our hypothesis. The possible reason is that chitosan
nanoparticles are formed by electrostatic interaction, which is not a strong interaction like
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a covalent bond. During the synthesis of CN-HEMA nanocomposite, chitosan
nanoparticles undergo sonication dispersion, organic solvents, and UV radiation. Those
interactions, especially sonication, may pose a negative influence on the integrity of
chitosan nanoparticles and impair their ability to withhold the release of bFGF.

Figure 6.4 Release of bFGF from silica nanoparticles (SN) and silica nanoparticleHEMA nanocomposite (SN-HEMA)
Silica nanoparticles could achieve a 180 hours’ prolonged bFGF release without an initial
burst like chitoan nanoparticles. Such prolonged release may be attributed to two
characteristics of silica nanoparticles: (1) The large pore volume of silica nanoparticles
allows for loading significant amounts of proteins into the particles. (2) The chemically
and mechanically stable inorganic oxide framework of silica nanoparticles shelters the
protein from degradation and denaturation

[23]

. The ability of silica nanoparticles to

withhold an initial burst release is also substantiated by other research papers [23,24]. Such
a release pattern may results from the high affinity of the silica nanoparticles to proteins.
Once incorporated into the SN-HEMA nanocomposite, bFGF release accelerated, despite
the fact that nanoparticles were embedded in a porous hydrogel scaffold. Other than
futher reduce the bFGF release speed, the SN-HEMA could only maintain a 150 hour
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sustained bFGF release. The possible explanation of this phenomenon is that the
sonication process, which aimed to suspend silica nanoparticles in the hydrogel
monomers, makes part of bFGF detach from the silica nanoparticles, the detached bFGF
releases very fast in the hydrogel and causes the initial burst of the nanocomposite.

6.1.5 Release mechanism
The rate-controlling mechanisms of drug release from hydrophilic matrices are polymer
dissolution (erosion) and diffusion of drug molecules across the polymer lay [25]. A semiempirical equation has been used widely to differentiate the contributions of both
mechanisms [26,27].

Where Mt is the amount of drug released at time t, M the amount of drug in dosage form,
Qt the fraction of drug released at t, n the diffusional exponent, and k the kinetic constant.
If diffusion dominates polymer erosion, the value of n would approach 0.5. On the other
hand, for erosion controlled formulations, n would approach the value of 1. Under a
mixed condition, the value of n falls in between 0.5 and 1 when both diffusion and
erosion occurs simultaneously.
The above formula can be transformed into the following formula. The value of n can be
calculated by linear regression.

The results of the calculation and the concluded release mechanism of samples in part
6.1.4 are listed in Table 6.1.
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Table 6.1 Release mechanism of bFGF from different nanomaterials
Sample
CN
CN-HEMA
SN
SN-HEMA

n value
0.2707
0.2937
0.8571
0.8879

Release mechanism
Diffusion controlled release
Diffusion controlled release
Erosion controlled release
Erosion controlled release

Silica nanoparticles are highly robust and its porous surface provides an inorganic
platform to house large amounts of protein

[28]

. The non-biodegradable nature of siclica

nanoparticles precludes the possibility of erosion during release. The contradiction can be
explained by the fact that the semi-empirical equation we applied to investigate the
release mechanism is devised for polymers. In other conditions, using of this equation
may lead to incorrect results.

6.2 Conclusions
In this chapter, a nanoparticle-HEMA nanocomposite was created to work as a wound
dressing with a sustained topical protein delivery. The protein model, fibroblast growth
factor (bFGF), was incorporated within chitosan and silica nanoparticles through
electrostatic interaction and hydrogen bond. To achieve a localized drug delivery, the
bFGF loaded chitosan and silica nanoparticle were incorporated within HEMA hydrogel
via photopolymerization. bFGF release from the chitosan and silica nanoparticles could
last 230 and 180 hours, respectively. The nanoparticle-HEMA nanocomposites did not
furture reduce the release rate of bFGF; the chitosan nanoparticle-HEMA and silica
nanoparticle-HEMA showed sustained bFGF release for 50 hours and 150 hours,
respectively. bFGF release from chitosan nanoparticle and corresponding nanocomposite
followed a diffusion controlled manner. The nanoparticle-HEMA synthesis process,
which exposes nanoparticles to sonication, organic solvents, stong turbulence, and UV
radiation, may compromise the bFGF-nanopaticle binding. The compromised bFGFnanopaticle binding makes bFGF release much faster from nanoparticle-HEMA than
from nanoparticles. However, due to the fact that nanoparticle-HEMA nanocomposites
makes localized sustained bFGF delivery possible, it can be concluded that these
nanocomposites are promising wound dressings.
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Chapter 7
Conclusions and Future Work
7.1 Conclusions
Protein-nanomaterial complexes have been investigated for their potential applicaton as
protein assay label, immobilized enzyme catalyst and localized drug delivery systems,
respectively.
First, a new AuNP assisted protein assay method was developed. Bovine serum albumin
(BSA) was bound to AuNP (BSA-AuNP) through the interaction between gold and amide
functional groups. The surface plasma resonance (SPR) of AuNP was used to detect the
release profile of BSA-AuNPs from gelatin microspheres. Within the range of 0.03125 0.5 mmol/L, SPR of AuNP showed a linear relationship to the concentration of BSAAuNP. The release profiles of BSA-AuNP from gelatin microspheres were mornitored
for 12 hours. It was found that a diffusion mechanism dominants the BSA-AuNP release.
Via the electrostatic interaction, carbonic anhydrase (CA) was immobilized onto ZnO
nanorods (CA-ZnO). The pH value of immobilization medium is between the isoelectric
point (pI) of CA (6.7-7.9) and ZnO (9.5). The CA immobilization ratio and the activity
of immobilized CA are dependent on the pH value of the immobilization buffer.
Compared with pH 6.9 and pH 7.5 media, the pH 8.0 medium could achieve the highest
CA immobilization ratio (60%), and the most active CA-ZnO. CA-ZnO produced in pH
8.0 immobilization medium was used to catalyze the CO2 capture by water. Using CO2
saturated water as reference, 6 mmol CO2 could be captured in 100mL water by a 2.2×2.2
cm CA-ZnO chip immobilized with 0.75 mg CA. The CA-ZnO chip could maintain its
activity for two times usage.
Through electrostatic interaction and hydrogen bond, fibroblast growth factor (bFGF)
was incorporated within chitosan and silica nanoparticles. Those bFGF loaded
nanoparticles were further immobilized within HEMA hydrogel via photopolymerization.
Chitosan and silica nanoparticles showed a sustained release of bFGF release for upto
230 and 180 hours, respectively. The nanoparticle-HEMA nanocomposites did not future
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reduce the release rate of bFGF. The release profile of chitosan nanoparticle-HEMA and
silica nanoparticle-HEMA reached plateau at 50 and 150 hours, respectively. Release
profiles of bFGF from chitosan nanoparticle and chitosan nanoparticle-HEMA follow the
diffusion controlled manner. Due to their ability of providing a localized sustained bFGF
delivery, these nanocomposites can be made into promising wound dressings.

7.2 Future Work
To get a clearer picture of how protein-nanoparticle interaction influences the application
of protein loaded nanomaterials, several aspects of this research need futher investigation.
1) Pre-labeling fixed amount of BSA with AuNP via chemical binding makes BSA
detectable by measuring the SPR of AuNP. However, this method does not help the
detection of unknown amount of protein with AuNP. Grafting AuNP surfaces with
protein antibodies could change the protein-AuNP interaction as well as the SPR
properties of AuNP. The interaction of protein with its antibodies might bridge the
separate AuNP and change its SPR. The change in SPR could be utilized to quantify
unknown amounts of protein with AuNP probes.
2) The static electrically immobilized CA-ZnO shows a limited service life in the CO2
capture system (showed in Figure 3.2). Two methods could be applied to extend the
service life of CA-ZnO: (a) ZnO could be surface modified to provide stronger binding
sites for CA. (b) The CO2 capture system (showed in Figure 3.2) could be improved to
reduce the turbulence.
3) The static electrical and hydrogen binding of of bFGF to chitosan and silica
nanoparticles are compromised by the series of processes to incorporate nanoparticles
into HEMA hydrogel. To improve the release properties of nanoparticle-HEMA
nanocomposites, future work could be carried out in two areas: (a) Nanoparticles could
be surface modified to realize a more endurable bFGF-nanoparticle binding. (b) The
procedure to produce dry nanoparticles as well as incorporate them into HEMA gel could
be optimized to exclude the sonication resuspension step and to make the process a
milder one.
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